Table 1

Correlation between NY-ESO-1 mRNA expression and pathological and clinical features in advanced prostate cancer.

Pathological and Clinical Features NY-ESO-1 mRNA Positive Tumors
Proportion Percentage
Benign prostatic hyperplasia 0/8 0%
All tumor specimens 20/53 38%
Gleason's score less than or equal to 7 6/21 29%
greater than or equal to 8 14/32 44%
Clinical stage C 4/15 27%
D1 1/3 33%
D2 15/35 43%